Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRNX NASDAQ:DAWN NASDAQ:IBRX NASDAQ:PTGX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRNXCrinetics Pharmaceuticals$83.85+0.1%$50.36$25.83▼$84.00$8.83B0.238.41 million shs5.22 million shsDAWNDay One Biopharmaceuticals$21.53$19.41$5.64▼$21.53$2.22B-1.741.52 million shs2.99 million shsIBRXImmunityBio$6.99-1.5%$7.75$1.95▼$12.43$7.44B0.019.75 million shs10.51 million shsPTGXProtagonist Therapeutics$135.56-0.4%$117.49$50.49▼$143.29$8.75B1.79708,671 shs416,660 shs10 Best Stocks to Own - Summer 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRNXCrinetics Pharmaceuticals+0.14%-0.02%+128.47%+119.79%+170.57%DAWNDay One Biopharmaceuticals0.00%0.00%0.00%0.00%+197.79%IBRXImmunityBio-1.55%-6.68%-19.75%+0.43%+144.41%PTGXProtagonist Therapeutics-0.40%+0.96%+11.22%+33.94%+145.80%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRNXCrinetics Pharmaceuticals$83.85+0.1%$50.36$25.83▼$84.00$8.83B0.238.41 million shs5.22 million shsDAWNDay One Biopharmaceuticals$21.53$19.41$5.64▼$21.53$2.22B-1.741.52 million shs2.99 million shsIBRXImmunityBio$6.99-1.5%$7.75$1.95▼$12.43$7.44B0.019.75 million shs10.51 million shsPTGXProtagonist Therapeutics$135.56-0.4%$117.49$50.49▼$143.29$8.75B1.79708,671 shs416,660 shs10 Best Stocks to Own - Summer 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRNXCrinetics Pharmaceuticals+0.14%-0.02%+128.47%+119.79%+170.57%DAWNDay One Biopharmaceuticals0.00%0.00%0.00%0.00%+197.79%IBRXImmunityBio-1.55%-6.68%-19.75%+0.43%+144.41%PTGXProtagonist Therapeutics-0.40%+0.96%+11.22%+33.94%+145.80%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRNXCrinetics Pharmaceuticals 2.29Hold$78.27-6.65% DownsideDAWNDay One Biopharmaceuticals 2.00Hold$23.298.15% UpsideIBRXImmunityBio 2.71Moderate Buy$14.20103.15% UpsidePTGXProtagonist Therapeutics 2.94Moderate Buy$123.00-9.27% DownsideCurrent Analyst Ratings BreakdownLatest DAWN, PTGX, CRNX, and IBRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2026CRNXCrinetics Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/17/2026PTGXProtagonist Therapeutics Johnson RiceSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$165.007/17/2026PTGXProtagonist Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform7/14/2026PTGXProtagonist Therapeutics BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$119.00 ➝ $151.007/10/2026IBRXImmunityBio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/8/2026CRNXCrinetics Pharmaceuticals TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold7/8/2026PTGXProtagonist Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy7/7/2026CRNXCrinetics Pharmaceuticals EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/7/2026CRNXCrinetics Pharmaceuticals Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/7/2026CRNXCrinetics Pharmaceuticals Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/7/2026CRNXCrinetics Pharmaceuticals Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 7/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRNXCrinetics Pharmaceuticals$18.07M489.30N/AN/A$9.71 per share8.64DAWNDay One Biopharmaceuticals$158.18M14.06N/AN/A$4.30 per share5.01IBRXImmunityBio$113.29M64.62N/AN/A($0.51) per share-13.71PTGXProtagonist Therapeutics$46.02M189.44N/AN/A$9.83 per share13.79Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRNXCrinetics Pharmaceuticals-$465.32M-$5.13N/AN/AN/A-2,747.18%-43.96%-39.61%8/4/2026 (Estimated)DAWNDay One Biopharmaceuticals-$107.32M-$1.03N/A2,153.00N/A-67.85%-23.43%-20.69%N/AIBRXImmunityBio-$351.40M-$0.85N/AN/AN/A-606.15%N/A-59.53%8/4/2026 (Estimated)PTGXProtagonist Therapeutics-$130.15M-$1.81N/AN/AN/A-154.88%-17.76%-16.47%8/5/2026 (Estimated)Latest DAWN, PTGX, CRNX, and IBRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2026Q2 2026PTGXProtagonist Therapeutics$2.11N/AN/AN/A$199.81 millionN/A8/4/2026Q2 2026CRNXCrinetics Pharmaceuticals-$1.23N/AN/AN/A$14.84 millionN/A8/4/2026Q2 2026IBRXImmunityBio-$0.09N/AN/AN/A$49.20 millionN/A5/7/2026Q1 2026CRNXCrinetics Pharmaceuticals-$1.22-$1.23-$0.01-$1.23$8.51 million$10.73 million5/7/2026Q1 2026IBRXImmunityBio-$0.08-$0.62-$0.54-$0.62$43.07 million$44.21 million5/5/2026Q1 2026PTGXProtagonist Therapeutics-$0.5004$0.05+$0.5504$0.05$11.70 million$56.37 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCRNXCrinetics PharmaceuticalsN/AN/AN/AN/AN/ADAWNDay One BiopharmaceuticalsN/AN/AN/AN/AN/AIBRXImmunityBioN/AN/AN/AN/AN/APTGXProtagonist TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRNXCrinetics PharmaceuticalsN/A18.6018.56DAWNDay One BiopharmaceuticalsN/A8.027.91IBRXImmunityBioN/A6.676.66PTGXProtagonist TherapeuticsN/A17.7617.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRNXCrinetics Pharmaceuticals98.51%DAWNDay One Biopharmaceuticals87.95%IBRXImmunityBio8.58%PTGXProtagonist Therapeutics98.63%Insider OwnershipCompanyInsider OwnershipCRNXCrinetics Pharmaceuticals3.80%DAWNDay One Biopharmaceuticals6.20%IBRXImmunityBio66.10%PTGXProtagonist Therapeutics5.19%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRNXCrinetics Pharmaceuticals210105.44 million101.43 millionOptionableDAWNDay One Biopharmaceuticals60103.33 million96.93 millionOptionableIBRXImmunityBio5901.05 billion355.05 millionOptionablePTGXProtagonist Therapeutics12064.31 million60.97 millionOptionableDAWN, PTGX, CRNX, and IBRX HeadlinesRecent News About These CompaniesRubric Capital Management LP Takes Position in Protagonist Therapeutics, Inc. $PTGX43 minutes ago | marketbeat.comWeiss Asset Management LP Takes $1.03 Million Position in Protagonist Therapeutics, Inc. $PTGX1 hour ago | marketbeat.comProtagonist Therapeutics, Inc. $PTGX Stock Position Lifted by Eagle Health Investments LP3 hours ago | marketbeat.comProtagonist Therapeutics, Inc. $PTGX Shares Acquired by Orbimed Advisors LLCJuly 27 at 6:08 AM | marketbeat.comGranahan Investment Management LLC Purchases Shares of 27,391 Protagonist Therapeutics, Inc. $PTGXJuly 26 at 5:51 AM | marketbeat.comProtagonist Therapeutics, Inc. $PTGX Stock Position Decreased by Bank of New York Mellon CorpJuly 26 at 3:20 AM | marketbeat.comFifth Third Bancorp Increases Stock Holdings in Protagonist Therapeutics, Inc. $PTGXJuly 25 at 3:28 AM | marketbeat.comAllspring Global Investments Holdings LLC Increases Stock Position in Protagonist Therapeutics, Inc. $PTGXJuly 25 at 3:05 AM | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) Upgraded at Wall Street ZenJuly 25 at 1:30 AM | americanbankingnews.comProtagonist Therapeutics (NASDAQ:PTGX) Rating Increased to Strong-Buy at Wall Street ZenJuly 25 at 1:29 AM | marketbeat.comJ&J, Gilead among recipients of EU drug recommendations this weekJuly 24, 2026 | seekingalpha.comKnott David M Jr Trims Stock Holdings in Protagonist Therapeutics, Inc. $PTGXJuly 24, 2026 | marketbeat.comProtagonist Therapeutics, Inc. $PTGX Shares Sold by Atika Capital Management LLCJuly 24, 2026 | marketbeat.comAssetmark Inc. Purchases 46,157 Shares of Protagonist Therapeutics, Inc. $PTGXJuly 22, 2026 | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) Sets New 52-Week High - Here's What HappenedJuly 20, 2026 | marketbeat.comSEB Asset Management AB Purchases New Shares in Protagonist Therapeutics, Inc. $PTGXJuly 20, 2026 | marketbeat.comJennison Associates LLC Purchases 740,847 Shares of Protagonist Therapeutics, Inc. $PTGXJuly 20, 2026 | marketbeat.comPrincipal Financial Group Inc. Raises Holdings in Protagonist Therapeutics, Inc. $PTGXJuly 19, 2026 | marketbeat.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Consensus Rating of "Moderate Buy" by BrokeragesJuly 19, 2026 | marketbeat.comBleakley Financial Group LLC Acquires Shares of 12,802 Protagonist Therapeutics, Inc. $PTGXJuly 18, 2026 | marketbeat.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: TG Therapeutics (TGTX), Protagonist Therapeutics (PTGX) and PROCEPT BioRobotics (PRCT)July 17, 2026 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSK Hynix’s Nasdaq Listing Could Reset the AI Memory TradeBy Thomas Hughes | July 7, 20265 Tech Stocks to Buy on the July PullbackBy Thomas Hughes | June 29, 2026Rocket Lab’s Stock Drop Comes With a Bullish TwistBy Ryan Hasson | July 10, 2026AirJoule Unveils Prime System, Clearing Path to CommercializationBy Thomas Hughes | July 1, 2026Vertex’s Crinetics Deal Balances Growth with Integration RiskBy Chris Markoch | July 8, 2026DAWN, PTGX, CRNX, and IBRX Company DescriptionsCrinetics Pharmaceuticals NASDAQ:CRNX$83.85 +0.12 (+0.14%) Closing price 07/27/2026 04:00 PM EasternExtended Trading$83.48 -0.37 (-0.44%) As of 06:29 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.Day One Biopharmaceuticals NASDAQ:DAWNDay One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.ImmunityBio NASDAQ:IBRX$6.99 -0.11 (-1.55%) Closing price 07/27/2026 04:00 PM EasternExtended Trading$6.94 -0.04 (-0.64%) As of 07:28 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.Protagonist Therapeutics NASDAQ:PTGX$135.56 -0.55 (-0.40%) Closing price 07/27/2026 04:00 PM EasternExtended Trading$135.83 +0.27 (+0.20%) As of 07:18 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dividend Stocks May Be the Quiet Rotation Trade Investors Are Missing Now AMD’s AI Bubble Could Burst Into Explosive Upside Refiner Stocks Are Near Record Highs—Can Iran-Driven Margins Keep Them There? A $1.5 Billion Wake-Up Call for Every AI Company on Wall Street AirJoule’s Kubota Deal Is a Major Validation—But the Hard Part Comes Next Atlassian’s AI Pivot Is Starting to Challenge Wall Street’s Bear Case Verizon May Be an AI Infrastructure Stock Hiding in Plain Sight Apple’s Earnings Setup Puts Its Record Rally and AI Patience to the Test Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
